Lior Teitelbaum
CBO at FutuRx
Claimed by owner A2i Therapeutics
Former names:
Novel Small-molecule Immuno-oncology Agents
A2i Therapeutics
About
A2i Therapeutics is developing novel small-molecule immuno-oncology agents. The company was formed as a joint venture between FutuRx, an Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies, and Atomwise, a US-based company using artificial intelligence for small-molecule drug discovery. The partnership will leverage Atomwise's AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
2
Investors
2
The Team
(1)
LT
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
Undisclosed
Nov 2020
2 Investors
Undisclosed
Non-Equity Funding
Grant
Undisclosed
Nov 2020
1 Grantors
Undisclosed
Media gallery
(0)Locations
Israel
Ilan Ramon Street 2, Ness Ziona, Israel
Locations
Israel
Ilan Ramon Street 2, Ness Ziona, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,